HOOKIPA Pharma Inc. (HOOK) – Company Press Releases
-
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
-
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
-
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
-
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
-
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
-
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
-
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
-
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
-
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
-
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
-
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
-
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
-
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Me
-
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
-
HOOKIPA Announces Executive Leadership Change
-
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
HOOKIPA Pharma to participate in upcoming investor conferences in September
-
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
-
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
-
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
-
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
-
Gamida Cell Appoints Terry Coelho as CFO
-
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
-
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
-
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
-
HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
-
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
-
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
-
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
-
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
-
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
-
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
-
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
-
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
-
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023
-
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023
-
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
-
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
-
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
-
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
-
HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine
-
HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine
-
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
-
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
-
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
-
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
-
HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update
Back to HOOK Stock Lookup
